Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

A method of inhibiting the initiation step of the reverse transcription of RNA of a type 1 human immunodeficiency virus, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I), wherein said formula (I) is as follows:

• wherein R1 is selected form the group consisting of:
• a hydrogen atom,
• an amino group NH2, and
• a C1-C10 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally comprising an heteroatom chosen from nitrogen, oxygen and sulfur,
• wherein R2, R3, R4 and R5 are independently selected from the group consisting of:
• a hydrogen atom,
• a halogen atom,
• a hydroxyl group,
• a C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising a heteroatom,
• an aryl group, optionally substituted by at least one C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom,
• an ester group of formula —O(O)O—Ra or of formula —O(O)O—Ra′, Ra and Ra′ being independently selected from the group consisting of a C1-C30 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, or Ra being a C1-C30 alkylaryl group, wherein the alkyl is linear or cyclic or branched, saturated or unsaturated, linked to the aryl group, optionally substituted and/or optionally comprising at least one heteroatom;
• a carboxyl group (—COOH),
• a nitro group (—NO2), and
• a cyano group (—CN),
• wherein R4 and R5 optionally form together a heterocycle,
• and/or a salt thereof and/or a solvate thereof.

A method of inhibiting the initiation step of the reverse transcription of RNA of a type 1 human immunodeficiency virus (HIV-1), comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (II), wherein said formula (II) is as follows:

• wherein X and Z together represent a fused benzene ring, optionally substituted by at least one substituent selected from the group consisting of:
• a hydrogen atom,
• a halogen atom,
• a hydroxyl group,
• a carboxyl group (—COOH),
• a nitro group (—NO2),
• a cyano group (—CN),
• a C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally substituted and/or optionally comprising at least one heteroatom, and
• an aryl group, optionally substituted,
• wherein R and R′ are independently selected form the group consisting of:
• a hydrogen atom,
• a halogen atom,
• a hydroxyl group,
• a carboxyl group (—COOH),
• a nitro group (—NO2),
• a cyano group (—CN),
• an amino group (—NH2),
• a C1-C20 alkyl group, linear or cyclic or branched, saturated or unsaturated, optionally comprising an heteroatom and/or optionally comprising at least one internal or terminal aryl group, said aryl group being optionally substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a carboxyl group, a nitro group, a cyano group and a C1-C10 alkyl group,
• a C1-C20 alkyl group comprising at least one internal or terminal heterocycle, said heterocycle being optionally substituted by at least one C1-C10 alkyl group,
• an aryl group, optionally substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a C1-C20 alkyl group optionally comprising a halogen atom and/or an heteroatom, a carboxyl group, a nitro group and a cyano group, and
• a heterocycle optionally substituted by at least one C1-C10 alkyl group,
• and/or a salt thereof and/or a solvate thereof.